Antibiotic Combination Therapy: A Strategy to Overcome Bacterial Resistance to Aminoglycoside Antibiotics

After the first aminoglycoside antibiotic streptomycin being applied in clinical practice in the mid-1940s, aminoglycoside antibiotics (AGAs) are widely used to treat clinical bacterial infections and bacterial resistance to AGAs is increasing. The bacterial resistance to AGAs is owed to aminoglycos...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Frontiers in pharmacology Ročník 13; s. 839808
Hlavní autori: Wang, Nuoyan, Luo, Jing, Deng, Fei, Huang, Yasi, Zhou, Hong
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Switzerland Frontiers Media S.A 23.02.2022
Predmet:
aminoglycoside antibiotics
antibacterial mechanisms
bacterial resistance mechanisms
Pharmacology
side effects
synergy
bacterial resistance mechanisms
side effects
synergy
aminoglycoside antibiotics
antibacterial mechanisms
ISSN:1663-9812, 1663-9812
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:After the first aminoglycoside antibiotic streptomycin being applied in clinical practice in the mid-1940s, aminoglycoside antibiotics (AGAs) are widely used to treat clinical bacterial infections and bacterial resistance to AGAs is increasing. The bacterial resistance to AGAs is owed to aminoglycoside modifying enzyme modification, active efflux pump gene overexpression and 16S rRNA ribosomal subunit methylation, leading to modification of AGAs’ structures and decreased concentration of drugs within bacteria. As AGAs’s side effects and bacterial resistance, the development of AGAs is time-consuming and difficult. Because bacterial resistance may occur in a short time after application in clinical practice, it was found that the antibacterial effect of the combination was not only better than that of AGAs alone but also reduce the dosage of antibiotics, thereby reducing the occurrence of side effects. This article reviews the clinical use of AGAs, the antibacterial mechanisms, the molecular mechanisms of bacterial resistance, and especially focuses a recent development of the combination of AGAs with other drugs to exert a synergistic antibacterial effect to provide a new strategy to overcome bacterial resistance to AGAs.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Pharmacology of Infectious Diseases, a section of the journal Frontiers in Pharmacology
Edited by: Younes Smani, Andalusian Center for Development Biology (CSIC), Spain
Reviewed by: Xiancai Rao, Army Medical University, China
Michal Letek, Universidad de León, Spain
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.839808